The Efficacy of Nano-water in Combination With Tamsulosin- Dutasteride for Lower Urinary Tract Symptoms

NCT ID: NCT06677177

Last Updated: 2024-11-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 210 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-16
• Study Completion Date: 2022-11-19

Brief Summary

The goal of this clinical trial is to learn if nano-water combined with tamsulosin and dutasteride can relieve the symptoms of lower urinary tract symptoms in adults with benign prostatic hyperplasia . The main questions it aims to answer are:

Does nano-water improve the results of treating patients with lower urinary tract symptoms? What is the difference between the medications alone and the medications with nano-water? Researchers will compare nano-water to a placebo (an ordinary bottled drinking water) to see if nano-water works to treat lower urinary tract symptoms .

Participants will:

Take (nano-water combined with Tamsulosin and Dutasteride) or a placebo an (ordinary bottled drinking water) combined with Tamsulosin and Dutasteride every day for 3 months Visit the clinic once every 4 weeks for checkups Keep a diary of their symptoms and the frequency of these symptoms

Detailed Description

Introduction Symptoms of lower urinary tract (LUT) are the most prevalent complaint among men diagnosed with benign prostatic hyperplasia (BPH). Men who have symptoms of LUT because of BPH (LUT/BPH) are more likely to seek medical attention when their symptoms become unbearable. The symptoms of LUT/BPH are usually related to voiding or storage. It has been discovered that the frequency of symptoms of LUT rises in a linear manner with age. Alpha-blockers and five alpha-reductase inhibitors have been combined to treat males with symptoms of LUT due to BPH conservatively. Structured water, a nanotechnology product, possesses unique qualities that set it apart from conventional water. Subjecting water to electromagnetic and other energy fields created and imbued it with its distinct properties.

Water that has had its molecules altered to form smaller clusters of water molecules is known as Nano-water. Conventional water comprises larger clusters of water molecules (H2O) joined by hydrogen bonds. In Nano-water, these clusters are smaller and usually comprise smaller-than-normal water structures like hexagonal or tetrahedral formations. More compact water clusters and a decrease in the propensity of water molecules to the group, often creating smaller, more stable structures-also enhanced-are the unique Nano-water components. Hydrogen Bonding: Changes to the hydrogen bonding network give the water additional structure.

Finally, improved Solubility: Minerals and other substances are more soluble due to the altered molecular arrangement. Nanotechnology, engineering, and manipulation of materials at the nanoscale (1-100 nm) provide Nano-water's potential. With this method, researchers can study and experiment with water-based nano-materials. Nano-water's unique structure is thought to improve water quality, which could have several health advantages. Among these is increased hydration due to Nano-water's smaller molecular clusters' easier passage through cell membranes, improving waste removal and nutrient transport efficiency. Studies indicate that compared to other substances, Nano-water may have a more significant potential for antioxidants. Some of its benefits are effectively combating harmful free radicals, reducing oxidative stress, and possibly reducing the risk of inflammation and chronic illnesses. Additionally, Nano-water may improve detoxification and support healthy kidney and liver function by more efficiently binding to toxins and heavy metals. It shows it induces better Circulation: Because Nano-water is said to have a lower viscosity, blood flow may be enhanced, resulting in more effective delivery of nutrients and oxygen to tissues and organs.

Water structured by nanotechnology: Magnalife is produced by modulators., particular energy fields, and frequencies that change regular water into Nano-water.

The study aimed to assess the effectiveness of Nano-water doubled with tamsulosin-dutasteride in improving symptoms of LUT in BPH patients.

Patients and methods From February 2016 to November 2022, a double-blind, randomized study was carried out in Sulaimani, Iraq, in the Kurdistan region.

A questionnaire determined our patients' International Prostatic Symptom Score (IPSS). Peak urine low rates (Qmax) were calculated, and residual urine (RU) was evaluated along with an ultrasound examination of the prostate's size.

The study excluded all patients with high prostatic-specific antigens and urinary tract infections. Two groups comprising 210 men were randomly assigned for three months based on their prostate volume (>30 and < 80 ccs) and an IPSS ≥ 13 or higher. Two groups of one hundred and five men each were given different amounts of the medication: group A received Nano-water with tamsulosin-dutasteride. In contrast, Group B was given regular water with the same medication.

Unlabeled water was given in a daily dosage of 20 milliliters per kilogram of body weight-with tamsulosin 0.4 mg and finasteride 0.5 mg. At the start (baseline data) and the end of the three months, both groups underwent evaluations for the IPSS, Qmax, and RU.

The Ethics Committee of the University of Sulaimani College of Medicine authorized the current study. All individuals provided informed consent.

The statistical analysis for the study was carried out using SPSS version 24. The data were coded, tallied, and presented descriptively. Inferential data techniques, including descriptive statistics like frequency, percentage, mean, standard deviation, and the Chi-squared test, were used in the analysis. The significance of the test results was assessed using probabilistic criteria based on P-value. Specifically, a P-value of 0.05 or higher was regarded as non-significant, less than 0.001 as highly significant, and less than 0.05 as significant.

Conditions

Lower Urinary Tract Symptoms

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Patients with LUTS due to BPH/ nano-water

Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia receiving nano-water combined with tamsulosin and Dutasteride

Group Type: EXPERIMENTAL

Nano-water, Tamsulosin Dutasteride

Intervention Type: DIETARY_SUPPLEMENT

Nano-water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months

Patients with LUTS due to BPH/regular water

Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia receiving regular water combined with tamsulosin and Dutasteride

Group Type: ACTIVE_COMPARATOR

Regular water, tamsulosin, Dutasteride

Intervention Type: DRUG

Regular water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months

Interventions

Nano-water, Tamsulosin Dutasteride

Nano-water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months

Intervention Type: DIETARY_SUPPLEMENT

Regular water, tamsulosin, Dutasteride

Regular water, given in a dose of 20 ml/kg daily for a period of 3 months Tamsulosin capsule in a dose of 0.4mg daily for a period of 3 months Dutasteride tablet in a dose of 0.5mg daily for a period of 3 months

Intervention Type: DRUG

Other Intervention Names

Tamsulosin; Dutasteride; Tamsulosin; Dutasteride

Eligibility Criteria

Inclusion Criteria

• prostate size >30 cc and < 80 cc
• IPSS >13

Exclusion Criteria

• High serum PSA
• Urinary tract infections

• Minimum Eligible Age: 50 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

University of Sulaimani

OTHER

Sponsor Role: collaborator

ALI KAMAL M. SAMI

OTHER

Sponsor Role: lead

Responsible Party

ALI KAMAL M. SAMI

Lecturer , Urology , Department of Surgery, College of Medicine, Medical Doctor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Ali K M. Sami

Role: PRINCIPAL_INVESTIGATOR

College of Medicine, University of Sulaimani

Locations

College of Medicine

Sulaymaniyah, Kurdistan Region, Iraq

Countries

Iraq

Other Identifiers

574

Identifier Type: -

Identifier Source: org_study_id